Cover Image
Market Research Report

Global Genitourinary Drugs Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 819282
Published Content info 125 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Genitourinary Drugs Market 2019-2023
Published: March 8, 2019 Content info: 125 Pages
Description

About this market

Any genitourinary disorders are noted in the urinary tract and the genital organs. The conditions in these parts of the human body could occur due to various bacterial infections or STDs. Genitourinary ailments also include various cardnomas such as prostate cancer, ovarian cancer, bladder cancer, and cervical cancer. The prevalence of these conditions is high worldwide and is continuously increasing. Lifestyle disorders such as stroke, autoimmune conditions such as multiple sclerosis, obesity, diabetes, or age-related ailments such as Alzheimer's are significantly responsible for genitourinary conditions. The prevalence of such health conditions is rising globally due to the sedentary lifestyle. Such a high prevalence of genitourinary diseases will drive the market growth during the forecast period. Technavio's analysts have predicted that the genitourinary drugs market will register a CAGR of almost 3% by 2023.

Market Overview

Technological advances in diagnostics

Advances in technology help in increasing patient adherence to treatment and gaining effective and swift results. They help in improving the condition of patients and reducing the diagnostic time. With the recent advances, both in the molecular laboratory diagnosis and point-of-care (POC) diagnostics technology, the vendors of the global genitourinary drugs market are also providing effective and quick results with less cost.

Patent expiries of novel drugs

Patent expiries of novel therapeutics lead to the introduction of generic drugs. Therefore, generic drugs are more cost-effective than novel therapeutics. Patents of many novel drugs used for the treatment of genitourinary conditions have expired, and a few of them are about to lapse during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the genitourinary drugs market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be moderately fragmented and with the presence of several vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Table of Contents
Product Code: IRTNTR30954

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Genital diseases - Market size and forecast 2018-2023
  • Urinary diseases - Market size and forecast 2018-2023
  • Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Astellas Pharma Inc.
  • AstraZeneca
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • Novartis AG

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations

PART 16: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ billions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Global genitourinary drugs market pipeline: Overview
  • Exhibit 18: Global genitourinary drugs market pipeline: Overview
  • Exhibit 19: Type - Market share 2018-2023 (%)
  • Exhibit 20: Comparison by type
  • Exhibit 21: Genital diseases - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 22: Syphilis cases reported in US 2013-2017
  • Exhibit 23: Genital diseases - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Urinary diseases - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 25: Urinary diseases - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Market opportunity by type
  • Exhibit 27: Customer landscape
  • Exhibit 28: Market share by geography 2018-2023 (%)
  • Exhibit 29: Geographic comparison
  • Exhibit 30: North America - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Top 3 countries in North America
  • Exhibit 33: Europe - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Top 3 countries in Europe
  • Exhibit 36: Asia - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Top 3 countries in Asia
  • Exhibit 39: ROW - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 41: Top 3 countries in ROW
  • Exhibit 42: Key leading countries
  • Exhibit 43: Market opportunity
  • Exhibit 44: Prevalence of various genitourinary cancers in US 2015
  • Exhibit 45: Prevalence rate of urinary incontinence in the geriatric population in the US (2010)
  • Exhibit 46: Global geriatric population in the last 5 years
  • Exhibit 47: Trending advanced diagnostics
  • Exhibit 48: Recent approvals of generic drugs
  • Exhibit 49: Devices for the treatment of genitourinary diseases
  • Exhibit 50: Impact of drivers and challenges
  • Exhibit 51: Trending novel formulations
  • Exhibit 52: Vendor landscape
  • Exhibit 53: Landscape disruption
  • Exhibit 54: Vendors covered
  • Exhibit 55: Vendor classification
  • Exhibit 56: Market positioning of vendors
  • Exhibit 57: Astellas Pharma Inc. - Vendor overview
  • Exhibit 58: Astellas Pharma Inc. - Business segments
  • Exhibit 59: Astellas Pharma Inc. - Organizational developments
  • Exhibit 60: Astellas Pharma Inc. - Geographic focus
  • Exhibit 61: Astellas Pharma Inc. - Key offerings
  • Exhibit 62: Astellas Pharma Inc. - Key customers
  • Exhibit 63: AstraZeneca - Vendor overview
  • Exhibit 64: AstraZeneca - Business segments
  • Exhibit 65: AstraZeneca - Organizational developments
  • Exhibit 66: AstraZeneca - Geographic focus
  • Exhibit 67: AstraZeneca - Key offerings
  • Exhibit 68: AstraZeneca - Key customers
  • Exhibit 69: Eli Lilly and Company - Vendor overview
  • Exhibit 70: Eli Lilly and Company - Business segments
  • Exhibit 71: Eli Lilly and Company - Organizational developments
  • Exhibit 72: Eli Lilly and Company - Geographic focus
  • Exhibit 73: Eli Lilly and Company - Segment focus
  • Exhibit 74: Eli Lilly and Company - Key offerings
  • Exhibit 75: Eli Lilly and Company - Key customers
  • Exhibit 76: Johnson & Johnson Services, Inc. - Vendor overview
  • Exhibit 77: Johnson & Johnson Services, Inc. - Business segments
  • Exhibit 78: Johnson & Johnson Services, Inc. - Organizational developments
  • Exhibit 79: Johnson & Johnson Services, Inc. - Geographic focus
  • Exhibit 80: Johnson & Johnson Services, Inc. - Segment focus
  • Exhibit 81: Johnson & Johnson Services, Inc. - Key offerings
  • Exhibit 82: Johnson & Johnson Services, Inc. - Key customers
  • Exhibit 83: Novartis AG - Vendor overview
  • Exhibit 84: Novartis AG - Business segments
  • Exhibit 85: Novartis AG - Organizational developments
  • Exhibit 86: Novartis AG - Geographic focus
  • Exhibit 87: Novartis AG - Segment focus
  • Exhibit 88: Novartis AG - Key offerings
  • Exhibit 89: Novartis AG - Key customers
  • Exhibit 90: Validation techniques employed for market sizing
Back to Top